{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-104557","form_type":"8-K","ticker":"RAPP","cik":"0002012593","company_name":"Rapport Therapeutics, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.813106+00:00","generated_at":"2026-05-17T18:30:05.618708+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Rapport Therapeutics Q2 net loss $26.7M; RAP-219 Phase 2a topline due Sept 2025, cash runway through 2026","bullets":["Net loss of $26.7M for Q2 2025 vs $18.1M YoY; R&D expenses $22.7M and G&A $6.8M.","RAP-219 Phase 2a trial in drug-resistant focal onset seizures fully enrolled; topline results expected September 2025.","Phase 2 trial of RAP-219 in bipolar mania initiated; topline results anticipated first half of 2027.","Cash, equivalents, and short-term investments $260.4M as of June 30, 2025, sufficient to fund operations through end of 2026.","Phase 1 safety: no SAEs; all TEAEs Grade 1 or 2; most common headache (n=12), dry mouth (5), brain fog (5), fatigue (5)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-104557","json":"https://secwatch.observer/filing/0000950170-25-104557.json","markdown":"https://secwatch.observer/filing/0000950170-25-104557.md","text":"https://secwatch.observer/filing/0000950170-25-104557.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2012593/000095017025104557/0000950170-25-104557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2012593/000095017025104557/rapp-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:30:05.618708+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}